Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,982.00
Bid: 1,982.00
Ask: 1,984.00
Change: -18.00 (-0.90%)
Spread: 2.00 (0.101%)
Open: 2,008.00
High: 2,012.00
Low: 1,973.00
Prev. Close: 2,000.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Avast CEO Departure Overshadows Results

Wed, 13th Mar 2019 10:41

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------Standard Life Aberdeen, up 2.9%. The asset manager is to end its co-chief executive structure, which was formed as a result of the merger between Standard Life and Aberdeen Asset Management in 2017. Keith Skeoch, former head of Standard Life, will become the sole chief executive officer with his co-CEO Martin Gilbert, founder and former head of Aberdeen, to take up the role of vice chair. "The decision to stop having two chief executives is definitely a good start as it should bring a tighter focus at the top of the company," said AJ Bell's Russ Mould. However, for 2018, the company reported assets under management and administration from continuing operations of GBP551.5 billion, down 9.3% from GBP608.1 billion at the end of 2017. Standard Life proposed a final dividend of 14.3p per share, bringing its total for the year to 21.6p, up 1.4% on 2017. The company intends to maintain its 2018 dividend during "the period of transformation", which the company said is 75% complete.----------FTSE 100 - LOSERS----------Hikma Pharmaceuticals, down 4.8%. The generic drugmaker's shares fell after annual earnings missed consensus estimates. For 2018, revenue was USD2.07 billion, a 6.7% increase from USD1.94 billion in 2017, which Hikma said reflected strong demand for its in-market products and new launches. Company-compiled consensus was for revenue of USD2.10 billion, putting Hikma's actual result just behind. Core operating profit was USD460 million 19% above its core operating profit of USD386 million in 2017, but 2.3% less than the USD471 million consensus. Hikma posted a pretax profit of USD293 million for the year, swinging from a pretax loss of USD738 million in 2017. The company declared a final dividend per share of 26 cents, taking the full-year dividend to 38 cents for the year. This is 12% higher than its dividend of 34 cents per share for 2017.----------WM Morrison Supermarkets, down 1.0%. The supermarket chain reported a fall in annual profit, but sales met analysts expectations amid strong like-for-like growth. For the year ended February 3, the UK's fourth biggest supermarket by market share posted pretax profit down 16% to GBP320 million from GBP380 million a year ago, as the company incurred some extra costs from investment in new store-pick capability and the roll-out of its wholesale supply deal with McColl's Retail Group. After rolling out its deal with McColl's, Morrisons said it was able to meet GBP700 million of annualised wholesale supply sales ahead of its initial guidance. Looking ahead, the supermarket said it expects to begin its supply to a further 300 McColl's stores by the end of 2019, as it remains on track to meet GBP1.00 billion wholesale supply sales "in due course". McColl's Retail was down 3.8%. ----------FTSE 250 - WINNERS----------Provident Financial, up 1.5%. The subprime lender swung to a profit in 2018 after making "immense progress" in the year as it continues to face regulatory pressure and a hostile takeover from smaller peer Non-Standard Finance. In 2018, Provident swung to a pretax profit of GBP90.7 million from a GBP147.9 million loss in 2017, on revenue of GBP1.12 billion and GBP1.20 million, respectively. Provident declared a nominal dividend of 10.0 pence per share for 2018, having paid none in 2017. For 2019, it intends to pay an interim dividend for 2019 in September and a final dividend in May 2020. Provident did not give any updates on the "unsolicited" offer from Non-Standard Finance, reiterating its belief that the offer "undervalues" Provident and presents a "significant" operational and execution risk. ----------FTSE 250 - LOSERS----------Avast, down 5.1%. The antivirus computer software company said it had a "successful" first year as a public company, while also saying its chief executive plans to step down. It was Avast's first annual results since its May 2018 stock market float and subsequent promotion to the FTSE 250 index. For 2018, Avast swung to a USD192.5 million profit from a USD28.9 million loss reported in 2017. This was on the back of revenue rising to USD808.3 million from USD652.9 million, while costs remained broadly stable on the prior year. Avast declared an 8.6 cents ordinary dividend for the period from May 15 to December 31, in line with its intention at the time of its IPO. Meanwhile, the company also said Steckler is to step down on June 30 as CEO and be replaced by president of the Consumer business, Ondrej Vlcek. The Consumer segment is Avast's largest unit. "Solid 2018 results with sales up 8.3% will likely be overshadowed by news of CEO Steckler's retirement," said UBS. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Charles Taylor, up 2.6%. The insurance market professional services provider declared a 5% rise in its total dividend for 2018 as revenue saw double-digit growth. Charles Taylor declared a final dividend of 8.08 pence per share, bringing the total payout to 11.56p, up 5.0% from 11.01p the year before. Revenue for the period grew by 25% to GBP263.6 million from GBP210.8 million the year before, driven by strong performances in all segments, particularly the new InsureTech division. Looking ahead, Charles Taylor said it has made a good start to 2019, with its full-year performance set to be in line with market expectations.----------OTHER MAIN MARKET AND AIM - LOSERS----------Red Emperor, down 84%, 88 Energy, down 37%, Pantheon Resources, down 24%. The partners in the Winx-1 well in the North Slope of Alaska reported disappointing results from wireline logging. Among London-listed companies, 88 Energy is the operator of the licence with a 36% stake, Red Emperor Resources owns a 31.5% interest, and Pantheon Resources has 10%. The companies said a provisional petrophysical analysis of logging program indicates low oil saturations. Moreover, testing and fluid sampling indicates that reservoir quality and fluid mobility is insufficient to warrant production testing.----------

More News
24 Feb 2022 10:31

TOP NEWS: Hikma Pharmaceutical records revenue growth and lifts payout

(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout.

Read more
24 Feb 2022 07:58

Hikma Pharmaceutical delivers year of 'solid growth' and 'strategic momentum'

(Sharecast News) - Drugmaker Hikma Pharmaceutical said on Thursday that it had delivered another successful year of "solid growth and continued strategic momentum", with both revenue and operating profits improving year-on-year.

Read more
24 Feb 2022 07:50

LONDON MARKET PRE-OPEN: Share buybacks for Lloyds Banking and Hikma

(Alliance News) - Stock prices in London are seen opening sharply lower, with the FTSE 100 called down almost 200 points, amid fear of a full-scale war in eastern Europe after Russia announced the beginning of a military operation in Ukraine.

Read more
17 Feb 2022 16:08

UK earnings, trading statements calendar - next 7 days

Friday 18 February  
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
TBC Bank Group PLCFull Year Results
Monday 21 February 
Bank of Cyprus Holdings PLCFull Year Results
Dechra Pharmaceuticals PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Tristel PLCTrading Statement
Wilmington PLCHalf Year Results
Tuesday 22 February 
Antofagasta PLCFull Year Results
Bank of Georgia Group PLCFull Year Results
Benchmark Holdings PLCQ1 Results
Blancco Technology Group PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Coca-Cola HBC AGFull Year Results
Hargreaves Lansdown PLCHalf Year Results
HSBC Holdings PLCFull Year Results (at 0400 GMT)
InterContinental Hotels Group PLCFull Year Results
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Synectics PLCFull Year Results
Transense Technologies PLCHalf Year Results
Wednesday 23 February 
Aston Martin Lagonda Global Holdings PLCFull Year Results
Barclays PLCFull Year Results
Capital & Counties Properties PLCFull Year Results
CAP-XX LtdHalf Year Results
Georgia Capital PLCFull Year Results
International Personal Finance PLCFull Year Results
Irish Residential Properties REIT PLCFull Year Results
Metro Bank PLCFull Year Results
Hochschild Mining PLCFull Year Results
Photo-Me International PLCFull Year Results
Rio Tinto PLCFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Ted Baker PLCTrading Statement
Unite Group PLCFull Year Results
Thursday 24 February 
Anglo American PLCFull Year Results
BAE Systems PLCFull Year Results
Centrica PLCFull Year Results
Conduit Holdings LtdFull Year Results
Derwent London PLCFull Year Results
Drax Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Inchcape PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Rathbone Group PLCFull Year Results
Ricardo PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
St James's Place PLCFull Year Results
Tremor International LtdFull Year Results
WPP PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
9 Feb 2022 09:48

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

Read more
3 Feb 2022 09:12

Hikma completes acquisition of Teligent's Canadian assets

Hikma completes acquisition of Teligent's Canadian assets

Read more
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.